Related Experiment Video
Updated: Jul 11, 2026
08:13
Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice
Published on: April 10, 2019
Gene therapy for duchenne muscular dystrophy: expectations and challenges
Louise R Rodino-Klapac1, Louis G Chicoine, Brian K Kaspar
1Center for Gene Therapy, Columbus Children's Research Institute, Columbus, OH, USA.
Archives of Neurology
|September 12, 2007
Summary
Gene therapy offers a promising approach for Duchenne muscular dystrophy, a severe X-linked disease. Early clinical trials focus on safety, dosing, and immunogenicity to advance this innovative treatment.
Area of Science:
- Neurology
- Genetics
- Biomedical Engineering
Background:
- Duchenne muscular dystrophy (DMD) is a severe, X-linked inherited muscle-wasting disease with limited therapeutic options.
- Gene therapy presents a promising avenue for treating DMD, encompassing gene replacement and functional repair strategies.
Purpose of the Study:
- To explore the potential of gene therapy for Duchenne muscular dystrophy.
- To review the initial phase 1 clinical trials for viral-mediated gene transfer in DMD patients.
Main Methods:
- Viral-mediated gene transfer, specifically intramuscular injection of a virus into a single muscle.
- Phase 1 clinical trials focusing on safety, dosing, immunogenicity, and viral serotype.
Main Results:
- The first viral-mediated gene transfer trials for muscular dystrophies, including DMD, are underway.
- Initial studies provide crucial data on safety, dosage, and immune responses in humans.
Conclusions:
- Early clinical studies are foundational for advancing gene therapy for DMD.
- Addressing challenges and potential pitfalls is essential for translating gene therapy into a clinical reality for DMD.
Related Concept Videos
00:59Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
00:59Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
01:21Satellite Stem Cells and Muscular Dystrophy
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
00:49What is Genetic Engineering?
Overview
01:29Microorganisms in Medicine and Therapeutics
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
01:24Cystic Fibrosis: Management
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Sinus disease and chronic sinusitis...